Partner David Rosen was quoted in a Korea Biomedical Review article, “How Korean pharma companies can succeed in US,” about how Korean pharmaceutical and biosimilar companies can find success in America.
Rosen, speaking at BIO KOREA 2019, said it is essential for Korean companies to develop drugs with a sense of responsibility for making the products safe. He also said if such expectations are not met, the companies can receive sanctions and penalties, including regulatory enforcement action, civil monetary penalties, and criminal liability.
“Import detention is something that everyone should be afraid the most as the Food and Drug Administration can block any import of the product,” he said. “Therefore, companies have to respond to all warning letters and the concerns that the FDA has, and address them.”
Rosen, speaking at BIO KOREA 2019, said it is essential for Korean companies to develop drugs with a sense of responsibility for making the products safe. He also said if such expectations are not met, the companies can receive sanctions and penalties, including regulatory enforcement action, civil monetary penalties, and criminal liability.
“Import detention is something that everyone should be afraid the most as the Food and Drug Administration can block any import of the product,” he said. “Therefore, companies have to respond to all warning letters and the concerns that the FDA has, and address them.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”